剖宫产瘢痕憩室与IVF卵巢刺激:生殖医学专家需关注的考量
该前瞻性观察性探索研究纳入103例有既往剖宫产史且超声可见瘢痕憩室的继发不孕患者,在接受IVF/ICSI卵巢刺激期间约40%出现宫腔内液体(ICF)。ICF的发生与憩室深度、周长、瘢痕至外口距离、分娩次数及既往剖宫产次数显著相关。在胚胎移植前排除ICF后,有与无憩室患者的冻胚移植生殖结局无显著差异。
要点
- 剖宫产瘢痕憩室患者IVF卵巢刺激期间ICF风险约40%,刺激全程及移植时需关注液体潴留。
- ICF发生与憩室深度(周期第2/3天P=0.038;扳机日前后P=0.049)、扳机日前后周长(P=0.040)等相关。
- 移植前排除ICF后,有与无憩室患者冻胚移植的妊娠率及不良妊娠结局无显著差异。
核心结论
- 有剖宫产瘢痕憩室的患者在IVF激素刺激期间发生ICF的风险约40%,刺激期间尤其移植时需注意排除液体潴留;移植前排除ICF后冻胚移植结局似乎未受影响。
研究设计与样本
- 前瞻性观察性探索研究,2018年6月至2019年3月于阿布扎比IVI中东生育诊所进行,并回顾性分析截至2019年7月的生殖结局。
- 纳入103例继发不孕(前次成功妊娠后不孕至少1年)、有≥1次剖宫产史且超声可见瘢痕憩室、接受IVF/ICSI卵巢刺激的患者。
- 卵巢刺激期间按临床常规行阴道超声监测,记录ICF发生及憩室测量变化;有憩室患者的冻胚移植结局与同期无憩室不孕患者回顾性比较。
主要发现
- 有剖宫产瘢痕憩室的患者在卵巢刺激过程中出现超声可见宫腔内液体的风险约40%。
- ICF发生与周期第2/3天憩室深度(P=0.038)、扳机日(-1/-2天)憩室深度(P=0.049)、扳机日(-1/-2天)憩室周长(P=0.040)、剖宫产瘢痕至宫颈外口距离(P=0.036)、分娩子女数(P=0.047)及既往剖宫产次数(P=0.035)显著相关。
- 卵巢刺激期间憩室大小相关参数呈统计学显著增加。
- 胚胎移植前排除ICF后,有与无憩室患者冻胚移植后的生殖结局(妊娠率及生化妊娠、异位妊娠、流产、持续妊娠/活产率)无显著差异。
临床怎么用
- 生殖医学专家对有剖宫产史及超声确认瘢痕憩室的患者,在IVF卵巢刺激期间需提高对憩室可能不良影响的认知,关注ICF的发生。
- 刺激期间及胚胎移植时需注意排除宫腔内液体潴留。
- 憩室周长的增加可能增加胚胎移植难度。
局限性
- 本研究主要目的并非探究卵巢刺激期间ICF的原因或评估生殖结局。
- 报告的生殖结局数量较少可能被视为局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the risk of developing intracavitary fluid (ICF) during ovarian stimulation in patients with an isthmocele after previous caesarean section (CS) delivery? SUMMARY ANSWER: In patients with an existing isthmocele, the risk of developing ICF during hormonal stimulation for IVF is almost 40%; therefore, special attention has to be paid to exclude fluid accumulation during stimulation and particularly at the time of transfer, in which case the reproductive outcomes of frozen embryo transfer (FET) cycles appear to be uncompromised. WHAT IS KNOWN ALREADY: Lately, there is an increasing focus on the long-term impact of CS delivery on the health and future fertility of the mother. Development of an isthmocele is one of the sequelae of a CS delivery. The presence of ICF in combination with an isthmocele has been described previously, and the adverse effect of endometrial fluid on implantation is well recognised by reproductive medicine specialists. Accumulation of ICF has been previously described in patients with hydrosalpinx, less commonly in patients with polycystic ovary syndrome undergoing ovarian stimulation for IVF/ICSI, and even in some patients without any identifiable reason. Assisted reproductive techniques (ARTs) are a means to overcome infertility. Reproductive medicine specialists commonly see patients with secondary infertility with a history of having had one or more previous CS and with ultrasound confirmation of an isthmocele. However, the available data pertaining to the prevalence of intracavitary fluid during ovarian stimulation in patients with ultrasound confirmation of an isthmocele is limited. Furthermore, data on the influence of ICF in a stimulated cycle on the ART outcome of a subsequent FET cycle is scarce and merits further studies. STUDY DESIGN, SIZE, DURATION: A prospective observational exploratory study was performed in IVI Middle East Fertility Clinic, Abu Dhabi, from June 2018 to March 2019, and retrospective analysis of the reproductive outcomes was performed until July 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients with secondary infertility, defined as a minimum of 1 year of infertility after a previous successful pregnancy, undergoing ovarian stimulation for IVF/ICSI and having a history of one or more previous CS with ultrasonographic visible isthmocele, were included (n = 103). Patients were monitored as a clinical routine with vaginal ultrasound examinations during ovarian stimulation for IVF/ICSI treatment. All patients included in the study were asked to complete a questionnaire regarding their previous obstetric history. Development of ICF was recorded as well as changes in the measurements of the isthmocele during the course of ovarian stimulation. Reproductive outcomes of FET cycles of the patients with an isthmocele were retrospectively compared to those of patients with infertility and without isthmocele in our clinic during the same time period. MAIN RESULTS AND THE ROLE OF CHANCE: Patients with an existing isthmocele after previous CS have a risk of ~40% of developing ultrasonographic visible fluid in the endometrial cavity during the course of ovarian stimulation. Development of ICF was significantly correlated with the depth of the isthmocele on Day 2/3 (P = 0.038) and on the day of trigger (-1/-2 days) (P = 0.049), circumference of the isthmocele on the day of trigger (-1/-2 days) (P = 0.040), distance from the C-scar to the external os (P = 0.036), number of children delivered (P = 0.047) and number of previous CS (P = 0.035). There was a statistically significant increase in the parameters related to the size of the isthmocele during ovarian stimulation. No significant differences in the reproductive outcome (pregnancy rate and rates of biochemical and ectopic pregnancies, miscarriages and ongoing/delivered pregnancies) after FET were found between the patients with and without an isthmocele, when ICF was excluded prior to embryo transfer procedure. LARGE-SCALE DATA: NA. LIMITATIONS, REASONS FOR CAUTION: This study was not primarily designed to investigate the causes of ICF during ovarian stimulation or to evaluate the reproductive outcomes. Further, the small number of reported reproductive outcomes may be seen as a limitation. WIDER IMPLICATIONS OF THE FINDINGS: The data highlights the need for an increased awareness on the part of reproductive medicine specialists towards the potentially adverse impact of an isthmocele on ART treatment, as there is a potential to develop intracavitary fluid during ovarian stimulation for IVF. The increase in the circumference of the isthmocele may increase embryo transfer difficulty. STUDY FUNDING/COMPETING INTEREST(S): No funding of the study has to be reported. The authors have no competing interests. TRIAL REGISTRATION NUMBER: This prospective study was registered with clinicaltrials.gov. under the number NCT03518385.
引用
- Lawrenz B, Melado L, Garrido N, et al. Isthmocele and ovarian stimulation for IVF: considerations for a reproductive medicine specialist. Hum Reprod. 2020. PMID: 31885047. doi:10.1093/humrep/dez241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。